Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 14Whole-Body Irradiation 8Mycophenolic Acid 8Peripheral Blood Stem Cell Transplantation 7Cyclosporine 6Cyclophosphamide 6Cytarabine 5Azacitidine 4Thiotepa 3Tacrolimus 3Filgrastim 3Antilymphocyte Serum 3tipifarnib 2laromustine 2aldesleukin 2Methylprednisolone 2Etoposide 2Cyclosporins 2Cord Blood Stem Cell Transplantation 2Bortezomib 2Biopsy 24-phenylbutyric acid 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2venetoclax 1sargramostim 1lintuzumab 1itacitinib 1ispinesib 1ilorasertib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Anemia, Refractory, with Excess of Blasts × Calcineurin Inhibitors × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡